State Street SPDR S&P Biotech ETF (XBI)

Invesco Pharmaceuticals ETF vs State Street Biotech ETF: Which Fund Is the Better Buy in 2026?

Stocks Look Shaky, But This Sector is Booming (Biotech)

This ETF Is Up Nearly 17% in a Month and Doesn't Own a Single Share of Nvidia

June's Top ETFs: Biotech & China Semiconductors Surge

Big Pharma's Looming Patent Cliff Period And How It Is Trying To Address It

Biotech Bigwigs ABBV, JNJ, BIIB & LLY Hit New 52-Week Highs

Biotech ETFs Gain Momentum via AI Drug Discovery & Surging M&A

Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)?

Wall Street Technician Declares Financials, Industrials, and Biotech Poised for Breakouts. 3 ETFs Could Soar.

XBI: A "Hidden" ETF Up +70% In 1 Year.

Is iShares Pharma ETF (IHE) or SPDR's Biotech ETF (XBI) the Better Long-Term Buy for Investors?

Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBC

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

3 Longevity ETFs to Buy and Hold (and Hold)

Healthcare ETFs: PJP Focuses on Pharmaceuticals, While XBI Zeroes in on Biotech

‘Buying stuff like it's going out of fashion': Biotech M&A on track for best year since pre-Covid

VHT vs. XBI: Vanguard Health Care ETF Tops SPDR Biotech in Yield and Cost

Is State Street SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

Biotech Investors Are Tuning Out the MAHA Chaos

If You Hold This Healthcare ETF, You're Losing Big